Business
Sernova Achieves Positive Efficacy Endpoint in Phase I/II Clinical Trial for Type 1 Diabetes
(via TheNewswire) Most advanced subject in the clinical trial continues to...
About this update from Sernova Biotherapeutics Inc
[{"type":"text","content":"Sernova Achieves Positive Efficacy Endpoint in Phase I/II Clinical Trial for Type 1 Diabetes(via TheNewswire)\n \n \nMost advanced subject in the clinical trial continues to show positive indicators of islet function following islet transplant into the Cell Pouch\n\n\n \nLONDON, ONTARIO - TheNewswire - February 13, 2020 - Sernova Corp (TSXV:SVA)(OTCQB:SEOVF)(FSE:PSH), a clinical-stage company and regenerative medicine therapeutics leader, is pleased to announce that Sernova's first treated patient in its Phase I/II clinical trial of its Cell Pouch with therapeutic cells for type 1 diabetes at the University of Chicago, has demonstrated survival of endocrine tissue (insulin-producing islets) in the sentinel Cell Pouch following 90 days transplant. \n\n\n \nThis efficacy outcome, namely, survival of endocrine tissue (insulin-producing islets) in the sentinel Cell Pouch following 90 days transplant, is measured by positive staining of islets during histological analysis. According to the independent pathologist who conducted the analysis, \"The explanted sentinel pouch shows abundant viable, organized islet cells intimately associated with blood vessels within a collagen matrix after 90 days of transplantation. These surviving islet cells strongly express insulin.\"\n\n\n \n\nClick Image To View Full Size\n\n \n \nA representative histological image from the islet-transplanted mini-sentinel Cell Pouch explanted from a patient at 90 days post-transplant. Islets with positive insulin staining (red), and new blood vessels (green) are detected. (A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch(TM) for Clinical Islet Transplantation.) https://www.thenewswire.com/client_files/2020-02-12-1.jpg \n\n\n \nThis achievement is important because it is an indicator of transplanted islet health in the therapeutic Cell Pouches remaining in the subject, including the islets ability to produce insulin into the bloodstream. This has been demonstrated by our previous reported findings of blood levels of both glucose-stimulated and fasting C-peptide as well as other efficacy indicators in this patient who had no measurable levels of this biomarker of insulin prior to the Cell Pouch islet transplant. \n\n\n \n\"We believe these accumulating positive results continue to validate our Cell Pouch technologies as a viable regenerative medici...